Journal
ACTA DERMATO-VENEREOLOGICA
Volume 97, Issue 9, Pages 1087-1094Publisher
ACTA DERMATO-VENEREOLOGICA
DOI: 10.2340/00015555-2724
Keywords
psoriasis; imiquimod; rapamycin; mTORC
Categories
Funding
- German Research Foundation (DFG), Germany [BU 1840/5-1]
- FWF Austrian Science Fund [W1241]
- PhD program Molecular Fundamentals of Inflammation (MOLIN) from the Medical University of Graz, Austria
Ask authors/readers for more resources
The mTOR (mechanistic target of rapamycin) inhibitor rapamycin has long been known for its immune suppressive properties, but it has shown limited therapeutic success when given systemically to patients with psoriasis. Recent data have shown that the mTOR pathway is hyperactivated in lesional psoriatic skin, which probably contributes to the disease by interfering with maturation of keratinocytes. This study investigated the effect of topical rapamycin treatment in an imiquimod-induced psoriatic mouse model. The disease was less severe if the mice had received rapamycin treatment. Immunohistological analysis revealed that rapamycin not only prevented the activation of mTOR signalling (P-mTOR and P-S6 levels), but almost normalized the expression of epidermal differentiation markers. In addition, the influx of innate immune cells into the draining lymph nodes was partially reduced by rapamycin treatment. These data emphasize the role of mTOR signalling in the pathogenesis of psoriasis, and support the investigation of topical mTOR inhibition as a novel anti-psoriatic strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available